Seems the CELLMID thread has vanished. Needs a dose of its own medicine
Peer review, ASX announced, for the hair restorer.
Works on eyelashes too.
US alone spends 150 million p.a. on eyelashes.
Blinking crazy I'd say.:)
Printable View
Seems the CELLMID thread has vanished. Needs a dose of its own medicine
Peer review, ASX announced, for the hair restorer.
Works on eyelashes too.
US alone spends 150 million p.a. on eyelashes.
Blinking crazy I'd say.:)
Not that I usually bother correcting loose usage of our language MBJ...however rather than using US it would probably be better saying "we"...:eek2: However my compliments to you and your wife for your enthusiastic pursuit of a full head of hair....or are they for the dog? With that kind of ground base support it sounds like an inhairently good investment.
US - United States??
The dog has sufficient hair for all of us if I can figure out how to make wigs.
Great marketing ploy "Hair of the Dog"
Sorry about the U.S. chaps, suppose I deserved a tongue " lashing" for that.
(Dont go there):)
Theres more to this than meets the eye.
The current market LEADER in drug treatments for eyelash, Latisse, sells over 150 million annually in the USA alone.
Most of that was for sales to Tammy Faye Baker
http://www.google.co.nz/url?sa=i&sou...05503013639963
More good news from Cellmid. Patent granted in Uk for use of midkine in hair growth restoration.
Advangen in the market in Japan, China and Australia, quarterly update in a couple of weeks, Quest to get its midkine marker lung cancer test out by Oct hopefully, Full year out at end of August, possible royalties from PEB and Quest.
Interesting times ahead and at .028 looks good for .029 at least
Finally broken through the .030 barrier, maybe the blocking seller has finished, either that or there is another load coming.
But thats neither hair nor there.
Revenue 2.8m, Profit/Loss -1.4m, Market Cap 20m. SP .03c Ballieu 07c - 26?c Hmmmmm, seems a bit undercooked by comparison especially with whats in the pipeline.:confused:
Big jump today on good volume ( 13 m so far) looked like the brakes had come off for a while.:)
might explain a bit: http://www.proactiveinvestors.com.au...267-57274.html
Yes, articles like this assist in giving a small co a higher profile. I often notice that news (good or bad) can take a few days to trickle through to the sp, particularly with small caps.
Fair sort of a jump in volume , nearly 20 million, think the instos might have woken up that this appears undervalued.
Sellers are a bit scarce and good volume building on the buy side but whether they will still be there at open is another matter.
Worth keeping an eye on CDY, not even back up to last CR point and revenues are building meanwhile.
DYOR
Solid buying based slowly chipping away at 3.4/3.5 (3.4 seems to providing quite a bit of resistance), wherever it ends, its nice to see the share price starting to move up. CDY price isn't likely to go up to levels that we want it to until the full potential is realised. The company creates a lot of value, but investors want to see even better numbers before they jump in to heavily. The hair products and royalties are what people are valuing the company by right now and it won't be valued too highly until all products break further ground. I won't mind if the share price goes up, but don't think its going anywhere quick, I think next year should be really good for CDY though, so will hold until then at least.
CDY is unusual for a small biotech company in that it is actually generating revenues from one product line (hair products) and some royalties which gives a limited degree of downside protection but has the potential for very significant upside if the main focus of the company's research (Midkine) is proven.
What is with the big drop today!? Value?
A little disappointing with the big drop today, but the main cause is that CDY is going through a capital raising for 5million, so value will be diluted and many have jumped ship cause what looks like a dream run turn into a nightmare.
In my opinion theres already a lot of value in this stock that any diluting at this stage to push the company further on is alright because there will be more value added with the extra capital used to fund the CAB102 clinical trials and I have taken the chance to increase my holding. Do beware that this capital only gets them to stage 1 so more capital raising to go.
Maria is buying on the market. Always a good sign when the CEO buys more. Must have a fair pile now.
Still cheap at .027AUD:eek2: ballieu gave them a midrange of 17 cps.
And up we go again, good volume too, hard to follow this one, its all over the place.
Interesting clip from the Australian putting CDY in the top 10
http://www.theaustralian.com.au/busi...-1227075562444
Zoetis signs with Cellmid to assess midkine in animal treatments. Upfront payment for exclusivity and milestone for progress.
This is BIG. Zoetis is the worlds largest animal health company. It is a spinoff from Pfizer
SP up 19% on open.:)
Hotcopper will be going nuts.
Now that’s a new story: David works with Goliath, plenty of benefit there. I guess as much as it would seem Goliath (21 Billion) could swallow David (20 million), working together sounds pretty good. Only a little gold dust from the pockets of Goliath would make us all very happy shareholders haha.
Mr Market couldn't care less by the looks." Show me the colour of your money" they seem to be saying.
It will probably be green.:)
The BQ is "How much?"
Until that is answered in either the quarterly or an additional announcement we will probably be bobbing up and down( as we do) for a while yet.
Encouraging though, hope it all pans out.:)
Yes given the climate so far its all about numbers and given so much uncertainty behind the deal. The big question is if its a big deal then why doesn't Zoetis just buy CDY out with their pocket money? So it makes people ponder, is this actually a big deal or something as a side interest that they are exploring for the beginning with little revenue and heavy research and development required before it becomes something of worthy value? Too much uncertainty but in a good direction which is all I care about, I'll happily wait for now.
I have started watching this one:-
(A Hair Raising Stock)
Quite volatile s.p movements, but my feeling is the Zoetis link is very positive.
Nothing wrong with a little - 'Hair -of -the dog"
This share ASX:CDY is well worth watching. A lot of positive stuff of late and probably best followed on hotcopper with the usual caveat for pump and dump. A big deal this week though with Zoetis for midkine antibody usage in companion animals, cats, dogs and horses, ( think huge racing industry) with an upfront exclusivity payment ( not revealed yet).
With a market cap of 20 m and holding most of the midkine patents and now some big pharma (albeit animals)very interested and coughing up for exclusivity ( animals only) from here it looks like up is the only way to go. Add a bit of hair restorer revenue, (actually works) and PEB royalties, maybe they wont need a capital raising for their core cancer trials.
Very clever people here. The next quarterly report will be very revealing.
Maybe, just maybe the CR will not take place, its getting pretty close to the 10th Dec now which I believe is the cutoff date.
Massive TV launch of their hair products in Japan reached 11.9 million viewers initially and is apparently being played for the next month. Cant be too hard to imagine that this could possibly fund a lot of R&D for them.
With all this carryon at .028 they seem a bit underrated IMHO:confused:
Thanks for the heads-up MBJ, I like the Science (so too do PEB) I like the money earning potential of the hair product sales to fund R&D and now that you put me on to Hot-copper, Its good to be in the company of other holders who like me can afford 'hundreds of thousands" of their (CDY) shares.
Disc; hold 'hundreds of thousands"
Price at posting $0.028
Major Ramp...... will b happy wen they reach $2.80...:t_up:
Why stop there? Clare Capital I think it was gave them 22.00. Even ballieu gave them a top of 27c:)
I have been pondering the reason that the share price has not rocketed on the recent good news, there is quite an over-hang from the 2013 purchase.
"As well as the cash payment in May 2013 to purchase Advangen, CDY issued 55,737,624 shares at a nominal issue price of 5 cents each to 12 Advangen Inc. shareholders, thereby acquiring 100% of the shares of that company. "
If I was one of those 12, I would have been selling on a regular basis to buy fresh hot Sake.
However Eighteen months is a long time and soon -very very soon those shares will be ours Mwahahhaa. (sorry - had too much Sake)
Once the great unknown amount of the upfront payment from Zoetis is revealed things might get cracking.
It seems the Aussie market is lagging behind in biotech stocks overall acccording to HC.
There is an interesting flow chart on HC that shows the relationships cellmid has with all the different products. Seems they have seven sources of income so far.
Think you will find it in the senile plaque thread- one of traes posts.
Ahh yes, found it, thanks, a very nice piece of work. I think I shall print off a few hundred copies and make them into my Christmas cards.
http://hotcopper.com.au/threads/midk...9#.VIUo4Geo69I
Folk on here will have to sign in to HC to view it,
You must have a lot of mates.
Are they Penn friends?
:) Be very careful - The PENN is mightier than the S word.
Trading halt regarding capital raising. Doh!
I had buy order in today for some of the options at 1c ( did not get filled) but someone has a buy in for 1 option at 1.2c! Manpulation? or something else?
Have a look at this mornings premarket on cdy. Buy at 29 nearly takes out sell at 27. If that happens then there will just be a few left which will look as if someone is trying to sell a small amount.
On that note there are twice as many roughly shares wanted as available and the price has returned to precap raising ann level.
The millions wanted at 25 24 23 22 were there to scoop up the expected effect of the cap raising. This did not occur, or hasn't so far,
and as a guess Id say it was because of a much lessened dilution than expected and also in a roundabout fashion a hint that the Zoetis deal upfront may be actually quite good.
Plus another patent issued for Midkine
:):)
I see. Thanks for that. Yes does look as though the Zoetis up-front payment could be in the $400,000-$4,000,000 range thereby reducing the ammount required for the CR. Still world events oft have a bigger impact.
If I am finding it hard to sleep I go here.
http://www.valuecruncher.com/companies/13848
Todays news is huge for a company with such a small M Cap.
AUSTRALIAN PATENT GRANTED FOR USE OF MIDKINE FOR HAIR GROWTH
- Patent for use of midkine to prevent and treat hair loss and to promote and enhance hair growth issued
- Comprehensive protection over midkine and related protein pleiotrophin with long patent life (to 2031)
- Major boosts to Cellmid’s hair growth asset portfolio
- Woop Woop! (sorry that was not meant to be a ramp)
Followed by:
USA PATENT FOR MIDKINE TO TREAT HEART FAILURE
· USA patent granted for use of midkine to treat heart failure
· Patent coverage for midkine as a chronic treatment for cardiac
disease
· Global patent family already in force in Europe and Japan
SYDNEY, Wednesday, 21 January 2015: Cellmid Limited (ASX: CDY) advises that the
USA Patent Office has granted the Company’s patent application 11/720,983
entitled " Composition for treating or preventing myocardial disorder or heart failure".
The granted claims cover the use of midkine (MK) as a treatment for heart failure
which commonly follows non-fatal heart attacks.
In published studies using in vivo animal models, MK treatment following heart attack
potently promotes new blood vessel growth in the affected tissue (angiogenesis),
limits cardiac dysfuntion, promotes ventricular tissue repair and increases long term
survival rates. Significantly, MK is effective even where treatment initiation is delayed
for weeks after infarct.
“This patent reinforces Cellmid’s comprehensive intellectual property position in using
MK therapeutically”, said Cellmid CEO Maria Halasz. “Through several global patent
families Cellmid’s patent coverage now extends across a number of related
mechanisms of action” she added.
“Midkine could become an important agent in the treatment of heart failure” said
Head of Product Development, Darren Jones. “In an acute setting MK prevents
cardiomyocyte death at the time of the heart attack. In the longer term MK
promotes beneficial fibrosis and angiogenesis in the cardiac muscle in the weeks
following a heart attack” he added.
Cellmid’s equivalent patents have already been granted in Europe and Japan.
Cellmid holds the most significant intellectual property assets related to MK
worldwide. Cellmid’s patent portfolio currently includes 87 patents in 20 patent
families, which cover the use of MK and anti-MK agents for therapeutic purposes in a
number of diseases, as well as the use of MK as a diagnostic marker in cancer and
other disorders.
More good news for CDY
Veterinary drug giant Zoetis ($ZTS) also drew a crowd at JP Morgan. The company has been under pressure from Pershing Square's Bill Ackman, an activist investor who bought a boatload of shares last year, reportedly with the intention of encouraging the company to put itself up for sale. During a Q&A session after Zoetis' Wednesday presentation, analysts pressed executives for details about their plans to maintain Zoetis as a viable standalone company.
Among the topics was Zoetis' acquisition strategy. In November, the company paid $255 million to acquire Abbott's ($ABT) animal-health assets, which included a suite of surgical tool. Zoetis would like to find more such opportunities--"small or medium" transactions that fill holes in the company's product portfolio, said executive vice president Kristin Peck during the Q&A.
Chief Financial Officer Paul Herendeen added that Zoetis "would lever up, potentially aggressively" if the right deal came along.
But Ackman has griped about Zoetis' cost structure, which was also a topic of concern during the Q&A. When asked about opportunities to improve efficiency, Herendeen said the company had an operating spend of $1.8 billion in 2013, minus cost of goods sold. About half of that was sales and marketing expenses, he said, including the costs of maintaining the company's sales force of 3,500.
The greatest opportunities for cost-cutting, Herendeen said, may be in general and administrative expenses, which were largely impacted by the company's spinoff from Pfizer ($PFE). Zoeits is currently working to streamline its technology platforms, which should increase efficiency and bring costs down, he indicated. "I would say that our current level of G&A spend is above what you should expect for a company of our scale and of our global footprint. And that's because we're just putting it in place," Herendeen said.
Zoetis is the outfit that CDY signed an agreement for the use of midkine in treating animals.
Should be a quarterly out in the very near future. Be interesting to see what Zoetis fronted up with as payment if it is in there.
Why this company is a market cap of 20 mil with several varied sources of income remains to be clarified. Appears to be enormous potential with midkine antibodies alone. They have midkine pretty well sewn up for patents and several companies are utilising it on human diagnostics, ie Pacific Edge, and Zoetis, a spinoff of Pfizer, is looking into the companion animal side of things.
Quest is involved as well. A good uplift in revenue this quarter seems quite on the cards if the sales went well in Japan after the big TV marketing show in December.
Last week the Cellmid Facebook page had a story Re- Takeda looking for large or small acquisitions, this year. My impression is that CDY are ripe for take-over. with only 20m MC, cash in the bank, current income streams, large patent portfolio.
These quotes come from that article.
Incoming Takeda chief ready to jump on the M&A train with reorg in place
Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday.
According to Weber, who will take the helm from chief exec Yasuchika Hasegawa when he's promoted from COO this June, Takeda won't let the industry's dealmaking wave pass it by, Reuters reports. And now that Weber has a company-wide rejig in the works, it's in a better position to be active, he said.
"We don't want to be passive and we don't want to watch the train passing," he told the news service.
For one, the drugmaker now has three distinct areas of focus--oncology, gastrointestinal medicine and emerging markets--that it can bolster through acquisitions,
While Weber didn't give much clue as to the size of the deals he's after--"perhaps a deal would be small or perhaps big," he said--he did highlight his company's goose egg in the net debt department, meaning it has room to maneuver.
(I,m not saying this will happen, but it has to be on the cards)
Cellmid news letter out today. Some very positive news. inc:-
"Our Advangen research team has started the year having secured Japanese
Government funding for new equipment. Under the “Monozukuri” grant program
Advangen Inc. may receive up to JPY 23 million ($240,000) in funding for
research equipment. The grant comes in the form of reimbursement for equipment
purchased during the qualifying period.
Our research focus is to continue the discovery of novel hair-growth actives by
using our highly accurate and reproducible bio-assays. In this process we are
participating in several academic and commercialresearch collaborations. The
outcomes support the company’s intellectual property strategy and help maintain
our position at the cutting edge of hair research.
In recent months we have had exciting results including data from our highly
predictive whole hair assay, which we have fine-tuned for the accurate
assessment of hair growth potential for our new compounds. The recent data on
our novel, patented compoundsare encouraging, showing FGF5 inhibition and
strong hair growth promotion."
Options jumped 37.5% (at time of posting)
Sales up 60% during a restructuring, pretty good effort.
Another factor has come to light as well. It has recently been established that the level of Midkine indicates the severity of the disease. Wow. That could be very useful.
Yes!
"researchers from the Nagoya University School of Medicine in Japan presented results
to show that MK levels closely mirrored severity and activity of kidney
damage in patients with lupus nephritis (LN). Lupus is an autoimmune disease; around
60% of lupus sufferers develop chronic kidney inflammation (nephritis) as a consequence. Importantly, the researchers
found that kidney damage was greatly reduced in a MK-knockout mouse model of LN, thereby showing that MK is not
merely a marker of LN kidney damage- it is a key driver of damage"
Cellmid have the antibodies,
My Mother has Lupus - No kidney trouble yet. But looks like kidney damage prevention is around the corner.! :t_up:
Here is a link to the February Newsletter which contains some very interesting developments.
http://www.cellmid.com.au/SiteMedia/...INAL%20ASX.pdf
Positive trial results announced on the hair growth thing
lol - what with this and positive things happening PEB this looks v good.... :)
Only appeared about half an hour ago, but shot up 33% (and options 50%)
Incredible results on an independant trial.
Has been a lonely wait but I cant stop smiling today!:t_up:
Makes you wonder how much an affirmative KP triage trial end result for PEB will affect this stock. Hope they hang onto the Advangen but I suspect they may flog it off to the likes of Johnson and Johnson for a princely sum. There should be some big companies taking an interest now.
Bill Gates apparently said in an interview that there is more money spent on baldness cures than malaria cures
25 mill shares traded on the day, thats a pretty good sign that things are looking up after a long, stultifying and very boring slide.
Encouraging news and about time. :)
Yes, I say hold on to the Advangen business, It will be a massive revenue generator
but at this low low Market cap, how can we/they avoid one of the big boys taking it.
I watched the "long, stultifying and very boring slide" and kept wanting to buy more (I did get a few a
month ago) but I am so over-weight in this I had to resist. The story is powerful-
évolis ONE has shown a statistically significant 80.2% reduction in hair loss
and demonstrated visible improvement in overall hair quality and volume with no adverse effects.
Very nice for a small Bio-tech to pursue health and healing while having a money printing machine on the side.
Nice uptick on Friday. Word seems to be getting out there. A good solid breakout is needed to get the SP out of the doldrums.
In the past I have always put hair restorers and tonics in the snake oil basket but it looks like with clinically validated results Cellmid may have the front running on one that works.
Be interesting to see what Baillieu Holst think of all this as well as all the major hair care companies.:)
:)Cdy have snagged a major pharmacy owner and distributor in Taiwan. China mainland next year.
They have their own brands which will start to include the product manufactured by Kikkoman on Cellmid's behalf according to the asx announcement.
It doesn't appear to be an exclusive right as they say other avenues are being explored.:)
Lexilis black label has gone on sale (on line) in China
Link to website here. Looks impressive.
And now with the Taiwan deal this will get interesting.
http://www.lexilis.cn/fa/?=news
(1480 yuan)per bottle?
That will get the cash flowing if sales take off. :)
This has been a pretty interesting share to watch. Pretty volatile but its getting close to looking like a buy to chartists--(30ma getting close to crossing above 120ma)
I can see how the product can have a pretty good ''wow'' factor...(actually mines getting a bit thin):) (thankfully not as thin as my little yellow man!)
:lol:"(thankfully not as thin as my little yellow man!) ":lol:
Ambiguous from someone labeled "advanced Member"
I was referring to my hair ,penn (was a bit ambiguous was'nt it)---not to worry,it was'nt me who did the labeling,on the member status:)
It IS amazing how in todays world, a hair growth product could out sell other products that could save your life ,rather than your hair.
"It IS amazing how in todays world, a hair growth product could out sell other products that could save your life ,rather than your hair."
True, But that is what I so like about CDY, they should soon be generating strong revenue from Advangen, that can be put towards their Midkine and midkine inhibitor development, thereby in a roundabout way saving lives by saving hair. I hope they don't sell the Advangen business, as the potential realy is enormous. Just imagine if they could licence the FGF5 inhibitor to Lynx, to go in men's hair product globaly. Trouble is watching the CDY SP is enough to make an investors hair fall out. :)
Just had alook at 10 year chart ; peaked above 40c in 2006 and tracking sideways since 2009!
Are they in profit yet; and debt levels?
Be int to know how many cap raises over that time and money burned through and what sort of remuneration packages management have consumed and if they've changed much.Any info at your fingertips penn?
Yes it would be silly to sell what could may well be their cash cow--my comment pointed to the fact it was ironic(our value system)but it was not meant to discourage a good earner(hopefully)--Market profile and distribution are paramount.
Lets not forget that there are many things influencing the market SP these days,not least the fact that the ASX is looking a bit sick as a whole.
People would rather watch entertainment than the real news of whats happening in our world today--that should say something about the sales potential of hair growth vs midkine deveopment
Rather than sell advangen,if they could partner up with a good well known distributor they'd be in a good place. (perhaps the biggest competitor to Regain)
Sorry Jt, I put up a long answer, from memory, after some wine, went to check one factoid, and lost the whole post! But let CDY do the talking!
"Cellmid Limited has completed the first ever formal pre-clinical toxicology studies for an anti-midkine
(MK) therapeutic molecule, with no mortalities, morbidities, dose limiting toxicities or
organ damage evident in any treated animal at any dose."
still a way to go, but good news so far.
http://hotcopper.com.au/attachments/...age-gif.72496/
Credit to Hotcopper poster Trae for a great piece of work.
Shows all the current associations up to the signing of Maywufa a few weeks ago.
Outstanding. IMHO
Yes MBj, outstanding work by Trae, and outstanding potential for this Company. A nice close today up 8% from open,
and (at last) Buyers outnumbering sellers 2-1
It has been a long wait, with still a long road ahead.
But, do you remember a November 5th (may be a long time ago) when a Firework was lit, you all saw the sparks, you waited,
a few of you shuffled forward for a closer look,
and then pOW Blue-sky!
I am shuffling forward.
:)
Wouldnt worry too much about PEB being described by a poster as "growing rapidly". His growing rapidly is obviously different to yours. The whole point of this is to show the many different aspects of CDY most of which could generate revenues far in excess of anything PEB comes up with in royalties. Zoetis who have taken a position with Cellmid on animal treatments are showing signs of interest in the latest toxicology results on CAB 102 and the linkup with GW Pharma in Spain on brain cancer.
All the $ signs on the chart are revenues being generated and as agreements are reached and payments made then the treasure chests change to $, in case maybe some of you hadnt noticed.
Cheers
Miner
Okeydokey will have a decent look when i can fit it in cheers JT
The way things have been going in the last couple of days I wouldnt leave it too long.:)
This from DAK144, poster on HC yesterday has a lot of information that pretty well sets out where CDY is at the moment.
Now that we have the single dose toxicology results and the Midkine antibody is safe even at extremely high doses, doors have now opened to multiple programs and possibly dozens of partnering opportunities.
Biotecnol has generated 78 humanised antibody variants of midkine. Of these, 6 of the MOST promising candidates were secreted at commercially viable concentrations and confirmed as stable and aggregate free.
One of these Midkine antibodies is being used for reducing solid cancer tumours.
One of these Midkine antibodies could be used for treating brain cancer.
One of these Midkine antibodies could be used for treating kidney disease and failure.
One of these Midkine antibodies could be used for treating Multiple Sclerosis.
One of these Midkine antibodies could be used for treating Surgical Adhesion.
One of these Midkine antibodies could be used for treating Bone Healing.
One of these Midkine antibodies could be used for treating Heart Ischemia.
One of these Midkine antibodies could be used for treating Colon Cancer.
One of these Midkine antibodies could be used for treating Metastatic Colorectal cancer.
One of these Midkine antibodies could be used for treating Hepatocellular (liver) Cancer.
One of these Midkine antibodies could be used for treating Prostate Cancer.
One of these Midkine antibodies could be used for treating Osteosarcoma.
All of these above mentioned diseases (Just to list some), have multiple published research papers on the significant role that Midkine plays in these disease settings.
You can now apply most of these cancer programs to animals....(which is why Zoetis, largest animal health company in the world, spinoff from Pfizer, recently signed an option to licence...)
Midkine also plays an important role in the diagnostics field. Midkine is already used as a diagnostic biomarker in the most accurate bladder cancer test in the world.
Midkine has also been quoted by Charlie Birse at Quest Diagnostics as the cream of the crop(Out of six biomarkers in total) in their Lung Cancer diagnostics test (waiting for regulatory approval).
Our CEO has listed 9 other diagnostics collaborations that Cellmid is involved in. (6 of which were commercially sensitive and the collaborator could not be disclosed).
Midkine antibody is also being used in a program at our Japanese Laboratory to reverse Baldness. This is in addition to any current hair loss products that inbibit FGF that cellmid has previously announced.
While i am on the topic of Hair loss and FGF inhibitors, our CEO in a newsletter said that once their global branding was in place then product strategy will be for products targeting prevention of greying hair(nothing on the market for this) and for eyelash growth(one product in the market only with sales of $124mill annually).
It is also now conclusive(with no doubt) that FGF5 is a key regulator of human hair growth. It is also conclusive that Cellmid is the only company in the world with an FGF5 inhibitor product.
Thanks for sharing.My top 12 inches from the neck up only ;is thinning and going gray so i need to look at this with a glass half full(at least). Any timelines for key events? cheers
Perhaps a good look at the cellmid website and a check on hotcopper CDY should get you most of the current news. Check the newsletters. Shareholders in Aus can get a big discount apparently and there is a massive marketing campaign about to start over there. Shipping is probably underway for Taiwan and Maywufa. Best I have at the moment.
Pretty clever actually, financing cancer antibody development by selling hair tonic and shampoos that have been proven to work and been peer reviewed.
Hotcopper get a bit carried away at times but worth a good look this share. Plenty of research to wade through.
OK. so....
Huge day of red for the ASX today.
Cellmid up 11%
announcement 29/06/2015
Cellmid’s lead humanised antibody CAB102 get's United States patent for anti-midkine antibodies to prevent and treat
cancer, inflammatory and autoimmune diseases,
“Having this patent granted in US for our MK antibodies across such a wide array of
diseases is a tremendous commercial outcome for Cellmid”, said Cellmid CEO Maria Halasz
I have decided to let my 'profits run'
DYOR & gltah
Seems to have reversed from getting beaten down to prodded up.
Hanging onto that .03 to close twice now.:)
Crikey, someone is keen this morning with a bid of 100000 at .04.
Hope its not smoke and mirrors, we have had enough of that "stuff".:)
Gone up 40% since 10 June and it seems to be holding onto its gains late in the day instead of the last minute push down that was occurring for a long time on .025.
FY just finished and big ramp up in hair product sales expected in this coming quarter. Big rollout to pharmacies in Oz plus going with Maywufa as a distributor into Taiwan with the hair product.
Never mind where all the midkine antibodies are leading us.
Top 80 shareholders mostly still accumulating.
A 6.7% rise today on this news:-
DR BRYCE VISSEL TO CHAIR CELLMID’S SCIENTIFIC ADVISORY BOARD.
Dr Vissel is currently the Head of the
Neurodegenerative Diseases research group at the Garvan Institute of Medical
Research as well as Conjoint Senior Lecturer at St Vincent's Clinical School, Faculty of
Medicine, University of NSW. Prior to that Dr Vissel worked for a decade at the highly
prestigious Salk Institute (La Jolla, California, USA), in the world’s leading
neuroscience laboratory.
Buyers nearly outnumber sellers 3:1
It does seem like The market is starting to see the potential here.
(I just hope the 'Drachma-queens' don't spoil the party)
Early days, but a few dots are getting joined up at last. Hope it continues.
What a lovely, lovely day to be a CDY holder
Revenue guidance ....UP
http://www.asx.com.au/asxpdf/2015070...kh3dqhwkgq.pdf
Hmmmm. Not bad for an under 25mil market cap.
1.05 mil for a quarter. This is half the full year guidance coming in the last quarter.
If not cashflow positive then must be close to it.
Share price reacting to near previous high and oppies at .033 - thats up 50% since early June.
Could be a fair bit of hair loss in China at the moment so sales may improve even further in the near future.
Suddenly its not as cold as it was.:)
Cheers
Miner
Options were $0.009 at the begining if the week (I picked up 1/2 a million)
They are now $0.014 Over 50% in a week when world shares are very shaky.
There is still some incoming tide here I feel. (DYOR)
But very happy with progress so far.
Why would a small biotec company hold a worldwide conference call to update a few shareholders on progress and plans?
Thats what is happening this Tuesday at Cellmid.
Will be watching for a trading halt on Monday afternoon.
From the revenue guidance up-grade.
"Cellmid will be hosting a conference call to brief the market on its sales and
distribution outlook.
The senior executive team will be providing an update on significant increase in sales
and distribution for its evolis® and Advangen® branded hair growth products.
And will provide insights on how sales from the consumer health division increased
significantly during 4Q 2015, and what that means for future revenue.
in particular the recent increase in direct to customer sales, will also
comment on plans for the rest of Asia.
And report on some of the very
important research and development that underpins ongoing success.
The products work and sales are taking off. (my words)
GLTAH
Shareholder 2yrs and user of evolis 3 months. Tried all the rest. This sh*t actually works. Sit tight for the ride.
Hair Ye Hair Ye
Solid end to the day at .036, new 52 week high. Clarification of sales tomorrow via conference call should be pretty revealing.
CEO Maria Halasz is known to understate and overdeliver with something out of left field on occasion. Any if this tomorrow should give the SP another bunt in the right direction.
To see the transcript of the Conference Call that took place at CDY on Tuesday click on the link.
Note the guy at the end from EAS asking the question about US Rollout of the hair products.
None other than Eddie Sugar of Fortescue, LPG and Allexion fame taking an interest in lil' ol' Cellmid.
http://www.cellmid.com.au/SiteMedia/...anscript-1.pdf
Awaiting developments from this. Share price is jumping around.
Just to keep anyone with the faintest interest up to date
CELLMID ASX: CDY closed at .037 tonight ( Friday) This is a new 52 week high and up considerably since June 1st.
Obviously the conference call on the hair products has had some effect this week but as this only constitutes part of the business it would seem to me to be a very encouraging sign that this small Australian biotech is about to rerate at the very least.
This is not financial advice, it is my own opinion to which I am entitled.
If you do research on this allow plenty of time as it is extremely complicated.
You're not the only one interested in this! :t_up:
The results from the latest quarter (largely due to the hair growth products) were very impressive, given how early they seem to be in the process of rolling out these products into international markets. There appears to be huge potential for increasing revenue just from this part of their business over the next few years.
Previously I was not that interested in this stock, but with the apparent success of the hair products, I have now been tempted into buying a small parcel of shares (bought today).
With a market cap of ~ $27 million currently and having just made ~$1 million revenue off their hair products in one quarter, and given these products have barely started to take off, this seems almost too good to be true... perhaps it is?! :scared:
I'm taking a punt though - if the midkine cancer projects proceed further with positive results, that would be icing on the cake.
Just my opinion - do your own research.
The signing of the agreement with Maywufa for distribution into Taiwan was the clincher for me to make this a 2 to 3 year long term investment.
Access to the Chinese market is possible through this as Maywufa have a branch office in China.
Asia seems to be the current focus given the involvement of Kikkoman in the manufacturing processes and the work being carried out in Japan on further products.
Probably one of the more interesting companies out there.
Havent heard of many biotechs financing their ongoing research and clinical trials through an unrelated product which is what Cellmid appear to be doing.
Access to the Chinese market is already achieved.
This from the Conference Call--
"In our quest to take advantage of the premium association of Japanese products in Asia we now export to China, with Chinese
import permits obtained for two of our tonic products. It is extremely difficult for Japanese quasi-drug products to be granted import permits into China.
These permits represent significant value for us and we are working on exploring the full potential of these permits.
In addition to our current Chinese distributor, we are in discussions with multiple parties to better penetrate this vast market where over 100 million people are reportedly worried about their thinning hair."
The head shares are now above the Options redemption price CDYO Oct 2016, so for my money a strong re-rate will have a huge leverage affect on the options.
Not advice just enthusiastic!
So just 1 percent of that Chinese market alone at 30.00 a bottle exceeds the current market cap.
Just for a bit of context.:)
Online in Aussie is where I got it. I'm trying to get a fledgling distribution going here with them but they've got bigger fish they're interested in first. Google evolis one.
"only FGF5 inhibitor hair growth products on the market globally. Weare leading the way in this exciting new field of hair science that hasthe potential to reduce hair thinning, increase hair growth rate andthe percentage of growing hair follicles. "
Ive highlighted the word and put red in. Why oh why do they use such a safe unproven term and not a proof of concept statement that it actually does. Rightfully or wrongly one immediately thinks of snake oil salesmen or slimming fads where they know punters will just go from one remedy to the next.Of course it doesn't have to work to be a successful sales company. Maybe its in similar situ to A2 atp.
Probably Frostbland is the distributor but I cant get Evolis to show up there. Dont know if they are still handling it, they had a three year contract from 2012. Maybe they are in the process of changing the distributor or have told them to get with it.:)